RCKT: rocketpharma.com Price to Earnings Adjusted for Growth Rate
A bet on elite geneticists and an ethical approach guarantee the stability of Rocket Pharmaceuticals (RCKT). The growth stock undervaluation coefficient confirms this potential, where 0.00 serves as the base parameter value. Risks are linked to the fierce battle for leadership in the rare pathology niche. Future success relies on regulatory pricing approval and a network of specialized medical centers.
Analytical breakdowns for Rocket Pharmaceuticals (RCKT)
- stock value and consensus price forecast:
- market capitalization information:
- shareholders' equity book value data:
- business debt structure and liquidity details:
Aggregate Debt to Equity Rocket Pharmaceuticals|RCKT - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital rocketpharma.com|RCKT - Company Aggregate Debts|Debts to Book Capitalization Rocket Pharmaceuticals Inc|RCKT - Company Long-Term Debt|Company Short-Term Loans and Borrowings Rocket Pharmaceuticals|Quick Liquidity Indicator rocketpharma.com
- earnings and market ratios statistics:
RCKT - Net Profit|Projected Future Earnings Rocket Pharmaceuticals|RCKT - P/E Multiple|Projected Price to Earnings Rocket Corp|RCKT - PEG Multiple|Company Value to EBITDA Rocket Pharmaceuticals Inc|RCKT - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Rocket Pharmaceuticals|RCKT - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months rocketpharma.com|RCKT - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Rocket Pharmaceuticals
General company analysis:RCKT Rocket Pharma
The operational dynamics of Rocket Pharmaceuticals (RCKT) and its elite geneticists treating rare pathologies are reflected in the P/E ratio relative to EPS growth. This metric correlates the price-to-earnings multiple with the rate of earnings growth: a value below one signals that the asset is undervalued, allowing investors to identify high-potential tech companies before a mass market revaluation occurs.
Competitors of Rocket Pharmaceuticals
PEG Multiple Tempus AI, Inc (TEM)|PEG Multiple QGEN (Qiagen Group)|Isis Pharmaceuticals (IONS) - Price to Earnings Adjusted for Growth Rate|RGEN: Price/Earnings to Growth Multiple|aviditybiosciences.com - Company Value to Earnings Growth Ratio|CRSP (CRISPR Therapeutics) - Price/Earnings to Growth Multiple|GeneDx Holdings - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Ultragenyx Pharma|Beam Tx - Market Cap to Earnings and Growth Ratio|PEG Multiple SRPT|TWST (twistbioscience.com) - Growth-Adjusted Payback Ratio|PEG Multiple TXG (10x Genomics)|PEG Multiple Intellia Therapeutics Inc NTLA|STOK - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio BLFS (BioLife)|Wave Life Sciences (WVE) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple mazetx.com|SION (Sionna Therapeutics) - PEG Multiple|PEG Multiple Prime Medicine Inc|PEG Multiple TSHA|Price/Earnings to Growth Multiple uniQure Pharma QURE|PEG Multiple MGTX (MeiraGTx Holdings plc)|regenxbio.com (RGNX) - Price to Earnings Adjusted for Growth Rate|SLDB: Price/Earnings to Growth Multiple|OCGN - PEG Multiple|PACB (Pacific Biosciences of California) - Price/Earnings to Growth Multiple|BNTC: Company Value to Earnings Growth Ratio|DSGN (Design Therapeutics) - PEG Multiple|4dmoleculartherapeutics.com (FDMT) - Growth-Adjusted Market Cap to Net Income|PEG Multiple LXEO|Price/Earnings to Growth Multiple korrobio.com KRRO|PEG Multiple EDIT (Editas)|PEG Multiple Silence Therapeutics Corp SLN|PRQR - Price/Earnings to Growth Ratio|CDXS: Price/Earnings to Growth Ratio|Sangamo Therapeutics, Inc. (SGMO) - Price/Earnings to Growth Ratio|NAUT - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Metagenomi, Inc|DTIL: Growth-Adjusted Payback Ratio|PEG Multiple GBIO|Price/Earnings to Growth Multiple boundlessbio.com BOLD|Price/Earnings to Growth Ratio Exicure XCUR|PEG Multiple Imunon Inc IMNN|PHIO: Price/Earnings to Growth Multiple|Mustang Bio, Inc. - Company Value to Earnings Growth Ratio|RNAZ: PEG Multiple|Growth-Adjusted P/E Ratio BNGO|Price/Earnings to Growth Ratio Applied DNA Sciences, Inc.|Growth-Adjusted P/E Ratio BLUE (bluebird bio Inc.)|PEG Multiple IPA|PEG Multiple Omega Therapeutics Corp (OMGA)|Price/Earnings to Growth Ratio Singular Genomics Systems OMIC|Growth-Adjusted Payback Ratio RGLS|SYRS - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Telesis Bio Inc.|TCON: PEG Multiple|Price/Earnings to Growth Multiple Unity Biotechnology, Inc
